Back to top
more

Puma Biotechnology (PBYI)

(Real Time Quote from BATS)

$2.99 USD

2.99
76,272

+0.04 (1.36%)

Updated Nov 4, 2024 11:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected

Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.

Zacks.com featured highlights Abercrombie & Fitch, Puma Biotechnology, Spotify and Oddity

Abercrombie & Fitch, Puma Biotechnology, Spotify and Oddity are part of the Zacks Screen of the Week article.

Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 50% and 7.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Vaishali Doshi headshot

Bet on These 4 Top-Performing Liquid Stocks for Solid Gains

Here are four top-performing liquid stocks, Abercrombie & Fitch (ANF), Puma Biotechnology (PBYI), Spotify (SPOT) and Oddity Tech (ODD), which investors can add to their portfolio to augment returns

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why

Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.

Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options

Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.

Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat

Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.

Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 68.75% and 5.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?

On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.

Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to Decline

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts

Puma Biotech (PBYI) closed the most recent trading day at $5.49, moving -0.63% from the previous trading session.

Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?

Puma Biotechnology (PBYI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study

The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.

J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer

The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.

PBYI vs. RGEN: Which Stock Is the Better Value Option?

PBYI vs. RGEN: Which Stock Is the Better Value Option?

Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise

Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business. Nevertheless, the guidance for 2024 looks encouraging.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Puma Biotech (PBYI) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates

Puma Biotechnology's (PBYI) fourth-quarter 2024 earnings and revenues fall shy of estimates. Stock declines.

Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates

Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.

Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up

Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.

Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat

Mirum's (MIRM) earnings fall shy of estimates in the fourth quarter of 2023 while revenues beat the same.

Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates

Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.